These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17045195)

  • 21. Design strategies for protein kinase inhibitors.
    Parang K; Sun G
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targets for cancer therapy in childhood sarcomas.
    Wachtel M; Schäfer BW
    Cancer Treat Rev; 2010 Jun; 36(4):318-27. PubMed ID: 20223596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small molecule signal transduction inhibitors for the treatment of solid tumors.
    Leary A; Johnston SR
    Cancer Invest; 2007 Aug; 25(5):347-65. PubMed ID: 17661211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 26. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H; Wesseling J; Boezen HM; van der Graaf WT
    Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
    Wu W; Lu C; Chen SY; Yu NF
    Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aurora kinases as targets for cancer therapy.
    Mountzios G; Terpos E; Dimopoulos MA
    Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.
    Alaoui-Jamali MA
    Biomed Pharmacother; 2006 Nov; 60(9):629-32. PubMed ID: 16949787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
    Campone M; Kerbrat P; Roché H; Bennouna J; Cuillière JC; Le Mevel B; Fumoleau P
    Bull Cancer; 2003 Oct; 90(10):851-64. PubMed ID: 14706914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Andersson M; Kamby C
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of kinases implicated in pancreatic cancer.
    Giroux V; Dagorn JC; Iovanna JL
    Pancreatology; 2009; 9(6):738-54. PubMed ID: 20090395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
    Youssoufian H; Hicklin DJ; Rowinsky EK
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5544s-5548s. PubMed ID: 17875787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted cancer therapy: promise and reality.
    Klein S; Levitzki A
    Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
    Bertoni E; Salvadori M
    J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.